There are no long-term studies of meglitinides assessing cardiovascular outcomes or mortality in patiens treated with his class of drugs. Whether meglitinides are associated with poorer outcomes after a myocardial infarction is not known. However,since its mode of action is similar to sulfonylureas, the same concern exists.